ClinicalTrials.gg
RecruitingNCT07563595ELENIUpdated Jun 25, 2026

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

An observational study in Breast Cancer, sponsored by iOMEDICO AG. Recruiting at 3 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by iOMEDICO AG · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Breast Neoplasms by iOMEDICO AG — 2 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · iOMEDICO AG.

Started
2026
the only one that year
Observational
6 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Breast Neoplasms by iOMEDICO AG, this one is the only one that started in 2026, is one of 6 observational ones, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 11 studies in Breast Neoplasms by iOMEDICO AG are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by iOMEDICO AG, or all of them as a file.
02

Study summary

The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and adverse event (AE) management in postmenopausal women with locally advanced and/or metastatic ER+ HER2- ESR1-mutated breast cancer and second line treatment with elacestrant according to SmPC (Summary of product characteristics) in a real-world setting.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Elacestrant
  • advanced breast cancer
  • Quality of life
  • ESR1 Mutation
  • Orserdu
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Postmenopausal women with locally advanced and/or metastatic estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2)- breast cancer with disease progression on endocrine therapy and cyclin-dependent kinase inhibitor (CDKi) and intention for second line (2L) treatment with elacestrant according to summary of product characteristics (SmPC).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated form
  • women
  • Age ≥18 years
  • Performance Status (ECOG) \< 2
  • Locally advanced and/or ER+ - breast cancer
  • proven ER positivity (defined as ≥1% staining by immunohistochemistry (IHC))
  • Histologically proven HER2 negativity (defined as a IHC0 or IHC1+ score by IHC or a negative result by in situ hybridization (ISH), optionally combined with a IHC2+ score)
  • Disease progression following ET + CDKi
  • No more than one prior ET line in the advanced/metastatic setting and intention for 2nd-line treatment with elacestrant according to current elacestrant SmPC as assessed by the treating physician (ESR1 testing can be done after inclusion)
  • For patients with proven ESR1mut: Study inclusion the latest 2 weeks after start of elacestrant treatment

Exclusion criteria

Exclusion Criteria

  • Prior chemotherapy in the advanced/ setting
  • according to elacestrant SmPC, except for ESR1 test result for patients included prior to ESR1 testing.
  • Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial (except follow-up phase)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • ESR1 wildtype

    Patients with a ESR1 wildtype tumor

    Drug: Standard of care (Investigator Choice)

  • ESR1 mutated

    Patients with a ESR1 mutated tumor

    Drug: Elacestrant

Interventions

  • According to the Summary of Product Characteristics (SmPC)

    Also known as: Orserdu®

  • DrugStandard of care (Investigator Choice)

    Treatment decision of investigator

06

What researchers measure

Primary outcomes

  1. Change from baseline in EORTC global health scale

    Change from baseline quality of life (QoL) over time for the global health scale of the EORTC QLQ- C30 questionnaire The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11

Secondary outcomes

  1. Time to deterioration in global health scale (EORTC QLQ-C30)

    Time to deterioration in global health scale of EORTC QLQ-C30 The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11

  2. Time to deterioration in functional scores (EORTC QLQ-C30)

    Time to deterioration in functional scores of EORTC QLQ-C30. The EORTC QLQ- C30 functional score ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11

  3. Time to deterioration in symptom scores (EORTC QLQ-C30)

    Time to deterioration in symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 symptom score ranges from 0 to 100, with lower scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11

  4. Change from baseline in functional and symptom scores

    Change from baseline in functional and symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 functional and symptom scores ranges from 0 to 100, with higher scores indicating better quality of life (for functional scores), and lower indication better quality of life for symptom scores.

    Time frame: From Time of enrolment until up to 11 months after enrolment.

  5. Change from baseline in visual analogue scale (VAS)

    Change from baseline in EQ-5D-5L visual analogue scale (VAS); The EQ-5D-5L VAS ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11.

  6. Change from baseline in index value

    Change from baseline in EQ-5D-5L Index Value The EQ-5D-5L index value ranges from -0.661 to 1, with higher scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11.

  7. Change from baseline in all scales of EQ-5D-5L

    Change from baseline in all scales of EQ-5D-5L The scales of EQ-5D-5L range from 1 to 5, with lower scores indicating better quality of life.

    Time frame: From Time of enrollment until month 11.

  8. Prevalence of ESR1 mutation

    Assess prevalence of ESR1mut in patients intended for elacestrant treatment as well as the testing methodology and results for ESR1 mutations.

    Time frame: Baseline

  9. Drug safety: Frequency

    Frequency of specific (serious) adverse drug reactions ((S)ADRs) (nausea, vomiting, decreased appetite)

    Time frame: From time of treatment start until 30 days after end of elacestrant treatment

  10. Drug safety: Incidence of adverse events

    Incidence of (serious) adverse events ((S)AEs), (serious) adverse drug reactions ((S)ADRs)

    Time frame: From time of treatment start until 30 days after end of elacestrant treatment

  11. Drug safety: Change from baseline in AST (Aspartate Aminotransferase)

    Change from baseline in AST

    Time frame: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)

  12. Drug safety: Change from baseline in ALT (Alanine Aminotransferase)

    Change from baseline in ALT

    Time frame: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)

  13. Drug safety: Change from baseline in bilirubin

    Change from baseline in bilirubin

    Time frame: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)

  14. Patients and disease characteristics: Age

    Assess patients characteristics in patients with intention for treatment with elacestrant: Age (descriptive statistics, categorical (\</≥ 65))

    Time frame: Baseline

  15. Patients and disease characteristics: Body mass index (BMI)

    Assess patients characteristics in patients with intention for treatment with elacestrant: BMI (descriptive statistics, categorical (underweight, normal weight, overweight, obese))

    Time frame: Baseline

  16. Patients and disease characteristics: ECOG Performance status

    Assess patients characteristics in patients with intention for treatment with elacestrant: ECOG Performance status

    Time frame: Baseline

  17. Patients and disease characteristics: CCI (Charlson score and contributing diseases)

    Assess patients characteristics in patients with intention for treatment with elacestrant: CCI (Charlson score and contributing diseases)

    Time frame: Baseline

  18. Patients and disease characteristics: Time since diagnosis

    Assess disease characteristics in patients with intention for treatment with elacestrant: Time since diagnosis (descriptive statistics)

    Time frame: Baseline

  19. Patients and disease characteristics: TNM staging

    Assess disease characteristics in patients with intention for treatment with elacestrant: TNM staging (including AJCC) at initial diagnosis

    Time frame: Baseline

  20. Patients and disease characteristics: Metastatic sites

    Assess disease characteristics in patients with intention for treatment with elacestrant: • Metastatic sites at inclusion

    Time frame: Baseline

  21. Patients and disease characteristics: Tumor Grading

    Assess disease characteristics in patients with intention for treatment with elacestrant: Tumor Grading at initial diagnosis and inclusion

    Time frame: Baseline

  22. Patients and disease characteristics: HR and HER2 status

    Assess disease characteristics in patients with intention for treatment with elacestrant: HR status and HER2 status at initial diagnosis and at inclusion

    Time frame: Baseline

  23. Patients and disease characteristics: Prior adjuvant chemotherapy

    Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant chemotherapy

    Time frame: Baseline

  24. Patients and disease characteristics: Prior adjuvant endocrine therapy

    Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant endocrine therapy

    Time frame: Baseline

  25. Patients and disease characteristics: prior CDKi/endocrine therapy in the palliative setting

    Assess disease characteristics in patients with intention for treatment with elacestrant: Type and duration of prior CDKi/endocrine therapy in the palliative setting (descriptive statistics, categorical ≤6 months / \>6 months; ≤12 months / \>12 months)

    Time frame: Baseline

  26. Patients and disease characteristics: Disease site

    Assess disease characteristics in patients with intention for treatment with elacestrant: Disease site (bone-only / visceral / non-visceral (not bone-only)) at inclusion

    Time frame: At time of enrollment

  27. Patients and disease characteristics: concomitant diseases

    Assess disease characteristics in patients with intention for treatment with elacestrant: concomitant diseases

    Time frame: Baseline

  28. Use of concomitant medication

    Assess the use of concomitant medication during treatment with elacestrant.

    Time frame: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)

  29. Assess parameters of physicians' treatment decision making using a questionnaire

    Frequency of distinct parameters affecting therapy choice; questionnaire completed by treating physician.

    Time frame: Baseline

  30. Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment

    Assess second-line treatments for all patients by ESR1 status (Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment (refers to first treatment received starting from second line)

    Time frame: max. 24 months; at patient patient-specific start of treatment

  31. Details on treatment with elacestrant: reason for end of treatment

    Assess reason for end of treatment (treatment with elacestrant)

    Time frame: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)

  32. Details on treatment with elacestrant: dose intensity

    Assess dose intensity (treatment with elacestrant) as prescribed by the treating physician

    Time frame: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)

  33. Details on treatment with elacestrant: frequency and type of dose modification

    Assess Frequency and type of dose modifications (dose reductions, interruptions) compared to SmPC of elacestrant.

    Time frame: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)

  34. Details on treatment with elacestrant: reasons for dose modifications and interruptions

    Assess reasons for dose modifications and interruptions (elacestrant treatment)

    Time frame: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)

  35. Treatments following elacestrant therapy: Type of first subsequent systemic antineoplastic therapy

    Details on treatments following elacestrant therapy (Type of first subsequent systemic antineoplastic therapy)

    Time frame: max. 24 months; from the patient-specific end of elacestrant treatment until end of study

  36. Treatments following elacestrant therapy: Frequency of first subsequent systemic antineoplastic therapy

    Details on treatments following elacestrant therapy:Frequency of first subsequent systemic antineoplastic therapy for ESR1mut patients (refers to first treatment received after Elacestrant so starting from third line)

    Time frame: max. 24 months; from the patient-specific end of elacestrant treatment until end of study

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 24 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
May 4, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07563595
Lead sponsor
iOMEDICO AG
Collaborators
Berlin Chemie AG
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Jun 19, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 25, 2026

Study contacts

Laura Serrer
Contact
eleni@iomedico.com
+49761152420
Thomas Decker, Professor
principal investigator · Gemeinschaftspraxis für Hämatologie und Onkologie GbR Ravensburg
Michael Patrick Lux, Professor
principal investigator · St. Louise Frauen- und Kinderklinik Paderborn

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion